Abstract

In this study, a novel triazolopyrimidinone derivative, 2-(2-chlorophenyl)-5-(morpholinomethyl)-[1,2,4]triazolo[1,5-a]pyrimidin-7(3H)-one, abbreviated as CPD-1, was synthesized as a drug candidate. By employing electrochemical techniques, we analyzed the electrochemical behavior of this compound and its interactions with both single-stranded DNA (ssDNA) and double-stranded DNA (dsDNA). Experimental parameters such as pH, concentration, scan rate, immobilization time were studied using Differential Pulse Voltammetry (DPV) and Cyclic Voltammetry (CV) to obtain the most precise analytical signals. We present an innovative approach to evaluate the toxicity effect of this drug candidate on DNA. We also propose a simplified equation to quantify toxicity effects based on changes in electrochemical signals, specifically peak current of guanine bases, before and after drug-DNA interactions. Our methodology contributes to the burgeoning field of electrochemical toxicity assessment and holds promise for advancing drug development and safety evaluation. Furthermore, stability tests for the drug candidate were conducted on different days. Notably, our investigation revealed significant alterations in guanine bases upon the interaction of CPD-1 with both ssDNA and dsDNA, underscoring the potential impact of these compounds on DNA structure. Based on our experimental data, we conclude that this molecule can be utilized as a drug due to its effects on DNA.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.